NeuroSearch A/S – Annual General Meeting 2013
NeuroSearch A/S (NEUR) will conduct the company's Annual General Meeting on Wednesday, 20 March 2013.
Shareholders who wish to submit motions for the Annual General Meeting must do so in writing for receipt by the Board of Directors no later than Tuesday, 5 February 2013.
Motions must be submitted either electronically to firstname.lastname@example.org or by ordinary mail to the company's postal address. Please mark 'Annual General Meeting'.
René Schneider, CEO, telephone: +45 4460 8700 or +45 2911 2097
NeuroSearch A/S (NEUR) is listed on NASDAQ OMX Copenhagen A/S. The company’s product pipeline comprises ordopidine and seridopidine, which have both completed phase I studies, as well as tesofensine, which has completed phase II, and NS2359 which has completed phase I.
All drug candidates exert their effect in the central nervous system.
(Unknown - 271 x 175)
NeuroSearch A/S Logo